Miramistin

42030USD

Description

Features

Reviews ¹

Scientific articles about the:

Instructions for Miramistin

Release form Miramistin:

rr d / local approx. 0.01%: fl. 50 ml, 100 ml 1 pc. in set urological applicator;
fl. 100 ml, 150 ml, 200 ml 1 pc.
in set with spray nozzle;
fl. 500 ml 1 or 12 pcs.

Description Miramistin:

Solution for topical use in the form of a colorless, transparent liquid, foaming on shaking.
benzyldimethyl [3- (myristoylamino) propyl] ammonium chloride monohydrate (calculated as anhydrous substance)
0.1 g [PRING] purified water - up to 1 liter. Miramistin

Polyethylene bottles 50 ml, 100 ml (1) with urological applicator with screw cap - cardboard packs.
Polyethylene bottles 50 ml (1) with urological applicator with a screw-on cap, complete with a spray nozzle - cardboard packs.
Polyethylene bottles 50 ml, 100 ml (1) with a urological applicator with a screw cap, complete with a gynecological nozzle - cardboard packs.
Polyethylene bottles 100 ml, 150 ml, 200 ml (1) complete with a spray nozzle or equipped with a spray pump and a protective cap - cardboard packs.
Polyethylene bottles 500 ml (1) with a screw cap with first opening control - cardboard packs.

Packaging for hospitals:
500 ml polyethylene bottles (12) with a screw cap with first opening control - cardboard boxes for consumer packaging. Miramistin

ATX codes
D08AJ (Quaternary ammonium compounds)

Clinical and pharmacological groups / Group affiliation
Topical antiseptic

Active substance Miramistin:

benzyldimethyl-myristoylamino-propylammonium chloride monohydrate

Pharmaco-therapeutic group
Antiseptic, Miramistin

Storage conditions Miramistin:

The drug Miramistin should be stored out of the reach of children at a temperature not exceeding 25 ° C.

pharmachologic effect Miramistin:

Miramistin ® has a wide spectrum of antimicrobial activity, including hospital strains resistant to antibiotics.

The drug Miramistin has a pronounced bactericidal effect Miramistin against gram-positive (Staphylococcus spp., Streptococcus spp., Including Streptococcus pneumoniae, and others), gram-negative (including Pseudomonas aeruginosa, Escherichia coli, Klebsiella spp.), Aerobic and anaerobic bacteria determined as monocultures and microbial associations, including hospital strains with multidrug resistance to antibiotics.

Has an antifungal effect on ascomycetes of the genus Aspergillus and genus Penicillium, yeast (including Rhodotorula rubra, Torulopsis glabrata) and yeast-like fungi (including Candida albicans, Candida tropicalis, Candida krusei, Pityrosporum orzbiculare (Mal) dermatophytes (including Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton verrucosum, Trichophyton schoenleini, Trichophyton violacent, Epidermophyton Kaufmann-Wolf, Epidermophyton floccosum, Microsporum gypseum, as well as microsporum fungi and other pathogenic species) including fungal microflora with resistance to chemotherapeutic drugs.

It has an antiviral effect , is active against complex viruses (herpes viruses, human immunodeficiency virus and others).

Miramistin ® acts on the causative agents of sexually transmitted diseases (including Chlamydia spp., Treponema spp., Trichomonas vaginalis, Neisseria gonorrhoeae).

Effectively prevents infection of wounds and burns. It activates the regeneration processes. Stimulates protective reactions at the site of application, by activating the absorption and digestion functions of phagocytes, potentiates the activity of the monocytic-macrophage system. It has a pronounced hyperosmolar activity, as a result of which it relieves wound and perifocal inflammation, absorbs purulent exudate, contributing to the formation of a dry scab. Does not damage granulation and viable skin cells, does not inhibit marginal epithelization.

Does not possess local irritating effect and allergenic properties, Miramistin

Indications Miramistin

For use in otorhinolaryngology:
complex treatment of acute and chronic otitis media, sinusitis, tonsillitis, laryngitis, pharyngitis;

complex treatment of acute pharyngitis and / or exacerbation of chronic tonsillitis in children aged 3 to 14 years.
For use in dentistry: Miramistin

treatment and prevention of infectious and inflammatory diseases of the oral cavity: stomatitis, gingivitis, periodontitis, periodontitis;
hygienic processing of removable dentures.

For use in surgery, traumatology:
prevention of suppuration and treatment of purulent wounds;
treatment of purulent-inflammatory processes of the musculoskeletal system.

For use in obstetrics, gynecology Miramistin:
prevention and treatment of suppuration of postpartum injuries, perineal and vaginal wounds, postpartum infections;
prevention and treatment of inflammatory diseases (vulvovaginitis, endometritis).

For use in combustiology:
treatment of superficial and deep burns of II and IIIA degrees;
preparation of burn wounds for dermatoplasty. Miramistin

For use in dermatology, venereology:
treatment and prevention of pyoderma and dermatomycosis, candidiasis of the skin and mucous membranes, mycoses of the feet;
individual prevention of sexually transmitted diseases (including syphilis, gonorrhea, chlamydia, trichomoniasis, genital herpes, genital candidiasis).

For use in urology:
complex treatment of acute and chronic urethritis and urethroprostatitis of a specific (chlamydia, trichomoniasis, gonorrhea) and non-specific nature.

Early syphilis
Late syphilis
Gonococcal infection
Chlamydial infections of the lower urinary tract
Chlamydial infections of the pelvic organs and other genitourinary organs
Chlamydial pharyngitis
Trichomoniasis
Anogenital herpes viral infection [herpes simplex]
Mycosis of the hands
Mycosis of the feet
Mycosis of the trunk
Candidal stomatitis
Skin and nail candidiasis
Vulvar and vaginal candidiasis
Candidiasis of other urogenital sites
Otitis externa
Otitis externa with mycoses
Suppurative and unspecified otitis media
Acute sinusitis
Acute pharyngitis
Acute tonsillitis
Acute laryngitis
Chronic pharyngitis
Chronic sinusitis
Chronic tonsillitis
Chronic laryngitis
Diseases of the pulp and periapical tissues (including periodontitis)
Gingivitis and periodontal disease
Stomatitis and related lesions
Pyoderma
Pyogenic arthritis
Osteomyelitis
Urethritis and urethral syndrome
Urethritis in diseases classified elsewhere
Inflammatory diseases of the prostate
Inflammatory disease of the uterus, except for the cervix (including endometritis, myometritis, metritis, pyometra, uterine abscess)
Inflammatory disease of the cervix (including cervicitis, endocervicitis, exocervicitis)
Other inflammatory diseases of the vagina and vulva
Vaginitis, vulvitis and vulvovaginitis in infectious and parasitic diseases classified elsewhere
Infection of the genital tract and pelvic organs due to abortion, ectopic and molar pregnancy
Perineal tears during delivery
Other obstetric injuries
Thermal and chemical burns of unspecified localization
Post-traumatic wound infection, not elsewhere classified
Preparatory procedures for subsequent treatment or examination, not elsewhere classified
Having a denture

Method of application, course and dosage Miramistin:

Otorhinolaryngology Miramistin

With purulent sinusitis - during puncture, the maxillary sinus is washed with a sufficient amount of the drug.

Tonsillitis, pharyngitis and laryngitis are treated by gargling and / or irrigation with a spray nozzle, pressing 3-4 times, 3-4 times / day. The amount of the preparation for one rinse is 10-15 ml.

In children with acute pharyngitis and / or exacerbation of chronic tonsillitis , the pharynx is irrigated with a spray nozzle. Children aged 3-6 years: press once on the head of the spray nozzle (3-5 ml per irrigation) 3-4 times / day; children aged 7-14 years, double pressing (5-7 ml for one irrigation) 3-4 times / day; children over 14 years old 3-4 times pressing (10-15 ml per irrigation) 3-4 times / day. The duration of therapy is from 4 to 10 days, depending on the timing of the onset of remission.

Dentistry Miramistin

For stomatitis, gingivitis, periodontitis, it is recommended to rinse the mouth with 10-15 ml of the drug, 3-4 times / day.

Surgery, traumatology, combustiology

For prophylactic and therapeutic purposes, the surface of wounds and burns is irrigated, wounds and fistulous passages are loosely tamponed, gauze tampons moistened with the drug are fixed. The treatment procedure is repeated 2-3 times / day for 3-5 days. A highly effective method of active drainage of wounds and cavities with a daily consumption of up to 1 liter of the drug.

obstetrics and gynecology Miramistin

In order to prevent postpartum infection, it is used in the form of vaginal irrigation before childbirth (5-7 days), in childbirth after each vaginal examination and in the postpartum period, 50 ml of the drug in the form of a tampon with an exposure of 2 hours, for 5 days. For the convenience of vaginal irrigation, the use of a gynecological nozzle is recommended. Introduce the contents of the bottle into the vagina with the help of a gynecological nozzle and irrigate.

When women are delivered by cesarean section , immediately before the operation, the vagina is treated, during the operation - the uterine cavity and an incision on it, and in the postoperative period, tampons moistened with the drug are inserted into the vagina with an exposure of 2 hours for 7 days. Treatment of inflammatory diseases is carried out in a course of 2 weeks by intravaginal administration of tampons with the drug, as well as by the method of drug electrophoresis.

Venereology Miramistin

For the prevention of sexually transmitted diseases, the drug is effective if it is used no later than 2 hours after intercourse. Introduce the contents of the bottle with the urological applicator into the urethra for 2-3 minutes: men (2-3 ml), women (1-2 ml) and into the vagina (5-10 ml). For convenience, the use of a gynecological attachment is recommended. Treat the skin of the inner surfaces of the thighs, pubis, genitals. After the procedure, it is recommended not to urinate for 2 hours.

Urology

In the complex treatment of urethritis and urethroprostatitis , 2-3 ml of the drug is injected into the urethra 1-2 times / day, the course is 10 days.

The drug Miramistin is ready for use.

Instructions for the use of the spray pack

1. Remove the cap from the bottle, remove the urological applicator from the 50 ml bottle.

2. Remove the supplied spray nozzle from the protective packaging.

3. Attach the spray nozzle to the bottle.

4. Activate the spray nozzle by pressing again.

Directions for use of the 50 ml or 100 ml pack with a gynecological attachment

1. Remove the cap from the bottle.

2. Remove the enclosed gynecological attachment from the protective packaging.

3. Attach the gynecological attachment to the bottle without removing the urological applicator.

Overdose Miramistin:

No information provided.

Drug interactions Miramistin:

With simultaneous use with antibiotics, an increase in their antibacterial and antifungal properties was noted.

Application during pregnancy and lactation Miramistin
Information on the use of the drug during pregnancy and lactation is not provided.

Side effect Miramistin:

Local reactions: in some cases, a slight burning sensation may occur at the site of application, which disappears on its own, after 15-20 seconds, and does not require discontinuation of the drug. Allergic reactions.